期刊文献+

人体关键药代动力学参数预测方法 被引量:1

Prediction of key pharmacokinetic parameters in human
下载PDF
导出
摘要 分布容积、清除率、半衰期和生物利用度是重要的药物代谢动力学参数,决定着药物在体内的暴露程度与暴露时间,在新药开发过程中尽早预测人体内这些参数对选择与优化潜在新药有重要价值。本文综述了采用临床前药代动力学实验数据、体外吸收与代谢数据、化合物理化性质、计算机模拟等多种方法预测人体内关键药代动力学参数的研究及其进展。 Volume of distribution,clearance,half of life and bioavailability are crucial pharmacokinetic parameters determining the extent and sustained time of drugs exposed in vivo.Thus,in the stage of drug discovery and development,it is of particular interest to estimate the pharmacokinetic parameters of drug candidates in human as early as possible to select the most promising compounds for further development.This paper reviews recent developments in prediction of human key pharmacokinetic parameters based upon preclinical animal pharmacokinetic data,absorption and metabolism data in vitro,physico-chemical property and in silico prediction.
出处 《中国临床药理学与治疗学》 CAS CSCD 2011年第6期699-709,共11页 Chinese Journal of Clinical Pharmacology and Therapeutics
基金 中央高校基本科研业务费专项资助(JKP2009007) 国家自然科学基金(30901832) "十一五"重大新药创制项目资助(2009ZX09304-001)
关键词 预测 药代动力学参数 体外-体内相关性 Prediction Pharmacokinetic parameters In vitro-in vivo correlation
  • 相关文献

参考文献51

  • 1Prentis RA, Lis Y, Walker SR. Pharmaceutical innovation by the seven UK-owned pharmaceutical companies (1964-1985)[J] . Br J Clin Pharmacol, 1988,25(3) : 387-396.
  • 2Ismail K, John L. Can the pharmaceutical industry reduce attrition rates? [J] . Nat Rev Drug Discov, 2004,3(8): 711-715.
  • 3Obach R, Baxter J. The prediction of human phar macokinetic parameters from preclinical and in vitro metabolism data[J] . J Pharmacol Exp Ther, 1997, 283(1) : 46-57.
  • 4Wajima T, Fukumura K, Yano Y, et al. Prediction of human pharmacokinetics from animal data and molecular structural parameters using multivariate regression analysis: volume of distribution at steady state[J] . J Pharm Pharmacol, 2003,55(7): 939-949.
  • 5Clausen J , BickeI MH. Prediction of drug distribution in distribution dialysis and in vivo from binding to tissues and blood[J] . J PharmSci, 1993,82(4): 345-349.
  • 6Loren MB, Jonathan R, Xuhai B, et al. Prediction of Vss from in vitro tissue-binding studies[J] . Drug Metab Dispos, 2010,38(1) :115-121.
  • 7Poulin P, Schoenlein K, Theil FP. Prediction of adipose tissue: plasma partition coefficients for struc- turally unrelated drugs[J]. J Pharm Sci,2001,90 (4) :436-447.
  • 8Poulin P, Theil FP. A priori prediction of tissue: plasma partition coefficients of drugs to facilitate the use of physiologically-based pharmacokinetic models in drugdiscovery[J]. J PharmSci, 2000,89(1) :16--35.
  • 9Poulin P, Theil FP. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanism-based pre- diction of volume of distribution[J]. J Pharm Sci, 2002,91(1): 129-156.
  • 10Rodgers T, Leahy D, Rowland M. Physiologically based pharmacokinetic modeling 1: predicting the tissue distribution of moderate-to-strong bases[J]. J Pharm Sei,2005,94(6):1 259--1276.

二级参考文献28

  • 1李范珠,潘旭旺.小鼠微透析技术及其在药物传递系统中的应用[J].药学学报,2006,41(10):921-926. 被引量:2
  • 2鲁鑫焱,蒋惠娣,曾苏.黄酮类化合物在原代肝细胞上的代谢和药物相互作用研究进展[J].药学学报,2006,41(12):1130-1135. 被引量:14
  • 3史健,高子彬,魏静,丁平田,陈大为.微渗析结合RP-HPLC研究盐酸平阳霉素在家兔血中的药代动力学[J].药学学报,2007,42(3):297-300. 被引量:3
  • 4Prentis RA , Lis Y, Walker SR. Pharmaceutical irmovation by the seven UK-owned pharmaceutical companies[J]. Br J Clin Pharmacol, 1988,25(3) :387 - 396.
  • 5Uehling MD. Model Patient [ EB/OL]. [2003]. http.// www. bio-itworld, com/archive/121503/trials, html.
  • 6Jackson PR, Tucker GT, Lennard MS, et al. Polymorphic drug oxidation: pharmacokinetic basis and comparison of experimental indices[J]. Br J Clin Pharmacol, 1986, 22 (5) :541 - 550.
  • 7Jackson PR, Tucker GT. Pharmacokinetic-pharmacogenetic modelling in the detection of polymorphisms in xenobiotic metabolism[J]. Arm Occup Hyg, 1990,34(6):653- 662.
  • 8Masimirembwa CM, Bredberg U, Andersson TB. Metabolic stability for drug discovery and development: pharmacokinetic and biochemical challenges[J]. Clin Pharmacokinet, 2003,42(6) :515 - 528.
  • 9Yang J, Jamei M, Yeo KR, et al. Kinetic values for mechanism-based enzyme inhibition: assessing the bias introduced by the conventional experimental protocol [ J ]. Eur J Pharm Sci, 2005,26(3/4) :334 - 340.
  • 10Venkatakrishnan K, yon Moltke LL, Court MH, et al.Comparison between cytochrome P450 (CYP) content and relative activity approaches to scaling from cDNA-expressed CYPs to human liver microsomes: ratios of accessory proteins as sources of discrepancies between the approaches[J]. Drug Metab Dispos, 2000,28(12) : 1493 - 1504.

共引文献6

同被引文献5

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部